The cost-effectiveness of mammographic screening strategies.

OBJECTIVE To compare and analyze the cost-effectiveness of different mammographic screening strategies. DESIGN A computer simulation model was developed to compare mammographic screening with observation without screening. Cost-effectiveness was expressed as marginal cost per year of life saved (MCYLS) and was calculated for the following mammographic screening strategies: (1) annual for ages 40 to 79 years; (2) annual for ages 50 to 79 years; (3) biennial for ages 50 to 79 years; (4) annual for ages 40 to 49 years with biennial for ages 50 to 79 years; (5) annual for ages 40 to 64 years with biennial for ages 65 to 79 years; (6) biennial for ages 40 to 49 years with annual for ages 50 to 79 years; and (7) annual for high-risk and biennial for normal-risk women aged 40 to 49 years with annual for ages 50 to 79 years. DATA SOURCES The probability and cost of all outcomes were established from previously published data or community experience. RESULTS The most cost-effective screening strategy is biennial mammography for women aged 50 to 79 years, with an MCYLS of $16,000. Adding annual mammography for women aged 40 to 49 years increases the MCYLS to $20,200, but is more cost-effective than other tested protocols that included women in their 40s; annual mammography for ages 40 to 49 years with biennial for ages 50 to 79 years is also more cost-effective than annual mammography for ages 50 to 79 years. CONCLUSION Screening programs that include women in their 40s can be as cost-effective as some that exclude such women. Choice of a screening strategy depends on financial resources and desired effectiveness.

[1]  L. Tabár,et al.  What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. , 1987, British Journal of Cancer.

[2]  M Moskowitz,et al.  Breast cancer: age-specific growth rates and screening strategies. , 1986, Radiology.

[3]  E A Sickles,et al.  Deficiencies in the analysis of breast cancer screening data. , 1993, Journal of the National Cancer Institute.

[4]  L. Baker,et al.  Breast cancer detection demonstration project: Five‐year summary report , 1982, CA: a cancer journal for clinicians.

[5]  M. Bibbo,et al.  Benefits of stereotactic aspiration cytology. , 1990, Administrative radiology : AR.

[6]  K. Hopper,et al.  Stereotactic breast biopsy with a biopsy gun. , 1990, Radiology.

[7]  D. Ikeda,et al.  Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations. , 1992, AJR. American journal of roentgenology.

[8]  T. Landberg,et al.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. , 1988, BMJ.

[9]  A. Giuliano,et al.  The prevalence of carcinoma in palpable vs impalpable, mammographically detected lesions. , 1991, AJR. American journal of roentgenology.

[10]  A. Mushlin,et al.  Is screening for breast cancer cost‐effective? , 1992, Cancer.

[11]  W. Donegan,et al.  Evaluation of a Palpable Breast Mass , 1992 .

[12]  A. Huggins,et al.  Edinburgh trial of screening for breast cancer: mortality at seven years , 1990, The Lancet.

[13]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[14]  L. Tabár,et al.  The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. , 1989, Journal of epidemiology and community health.

[15]  D M Eddy,et al.  The value of mammography screening in women under age 50 years. , 1988, JAMA.

[16]  M. Slattery,et al.  A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. , 1993, JAMA.

[17]  S. Feig.  Determination of mammographic screening intervals with surrogate measures for women aged 40-49 years. , 1994, Radiology.

[18]  L. Tabár,et al.  Update of the Swedish two-county program of mammographic screening for breast cancer. , 1992, Radiologic clinics of North America.

[19]  S. Shapiro,et al.  Ten- to fourteen-year effect of screening on breast cancer mortality. , 1982, Journal of the National Cancer Institute.

[20]  C. Smart,et al.  Breast cancer detection guidelines for women aged 40 to 49 years: Rationale for the american cancer society reaffirmation of recommendations , 1994, CA: a cancer journal for clinicians.

[21]  C. J. Rosenquist,et al.  Screening mammography in women aged 40-49 years: analysis of cost-effectiveness. , 1994, Radiology.

[22]  A Liberati,et al.  Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. , 1995, JAMA.

[23]  G. W. Eklund,et al.  Screening mammography in women 40-49 years old. , 1995, AJR. American journal of roentgenology.

[24]  C. J. Rosenquist,et al.  Needle core biopsy guided with mammography: a study of cost-effectiveness. , 1994, Radiology.

[25]  H. Ellis,et al.  Breast problems in 1,000 consecutive referrals to surgical out-patients. , 1984, Postgraduate medical journal.

[26]  N Volkers.  NCI replaces guidelines with statement of evidence. , 1994, Journal of the National Cancer Institute.

[27]  G. W. Eklund,et al.  Percutaneous large-core breast biopsy: a multi-institutional study. , 1994, Radiology.

[28]  E A Sickles,et al.  The comparative value of mammographic screening for women 40-49 years old versus women 50-64 years old. , 1995, AJR. American journal of roentgenology.

[29]  Powell Rw,et al.  Breast cancer detection demonstration project. , 1973 .

[30]  E. Sickles.  Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases. , 1991, Radiology.

[31]  S Shapiro,et al.  Report of the International Workshop on Screening for Breast Cancer. , 1993, Journal of the National Cancer Institute.

[32]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[33]  C. Smart.  Highlights of the evidence of benefit for women aged 40–49 years from the 14‐year follow‐up of the breast cancer detection demonstration project , 1994, Cancer.